Icosavax, Inc. (ICVX)

Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Last trade price

Company Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.

Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine.

The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.

Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

Icosavax, Inc.
Icosavax logo
Country United States
Founded 2017
IPO Date Jul 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 60
CEO Adam K. Simpson

Contact Details

Address:
1930 Boren Ave., Suite 1000
Seattle, Washington 98101
United States
Phone (206) 737-0085
Website icosavax.com

Stock Details

Ticker Symbol ICVX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001786255
CUSIP Number 45114M109
ISIN Number US45114M1099
SIC Code 2836

Key Executives

Name Position
Adam K. Simpson President, Chief Executive Officer, Co-Founder and Director
Niranjan Kanesa-thasan M.D. Chief Medical Officer
Dr. Cassia Cearley Ph.D. Treasurer and Chief Business Officer
Neil King Ph.D. Chair of Scientific Advisory Board and Co-Founder
Dr. David Baker M.D., Ph.D. Co-founder and Member of Scientific Advisory Board
Thomas Joseph Russo C.F.A. Chief Financial Officer
Jennifer Raymond Senior Vice President of Technical Operations
Elizabeth Bekiroglu General Counsel and Corporate Secretary
Lori Stewart Senior Vice President of People and Culture
Dr. Ami Shah Brown MPH, Ph.D. Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Feb 21, 2024 SC TO-T/A Filing
Feb 20, 2024 EFFECT Notice of Effectiveness
Feb 20, 2024 25-NSE Filing
Feb 20, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Feb 20, 2024 POS AM Post-Effective amendments for registration statement
Feb 20, 2024 8-K Current Report
Feb 20, 2024 SC 14D9/A Filing
Feb 20, 2024 SC TO-T/A Filing
Feb 15, 2024 SC TO-T/A Filing
Feb 15, 2024 SC 14D9/A Filing